![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
This invention from Astra AB discloses several novel substituted tricyclic imidazol [1,2–1] pyridines containing a dihydroxymethyl substituent at the 3-postion. The preferred compound is 3-hydroxymethyl-2-methyl-9-phenyl-7H-8,9-dihydropyrano-(2,3-c)-imidazo-(1,2-a)-pyridine. This compound inhibits exogenously and endogenously stimulated gastric acid secretion. Potential uses of the claimed compounds may be more specific, in that they may be used for the prevention and treatment of gastric acid-related diseases such as gastritis, gastric ulcers, duodenal ulcers and reflex oesophagitis. Additional claims are also made for the use of the compounds where anti-acid secretory activity is desired. These conditions include gastrinomas, upper gastrointestinal bleeding, prevention of gastric acid aspiration and stress ulcers. The invention makes a general statement that the compounds may be used for the prevention and treatment of gastrointestinal inflammatory diseases, but the claim is not well substantiated.